Key Takeaways
- Döhler has begun commercial production of SB1, a high-protein postbiotic ingredient, in Europe to support US launches.
- SB1 contains over 88% protein and offers various health benefits, having received FDA’s GRAS status.
- Superbrewed Food aims to repurpose a US anaerobic fermentation facility to boost production capabilities by 2027.
Introduction of SB1
Döhler, a major ingredients company, has commenced the commercial production of SB1, a postbiotic ingredient developed by Superbrewed Food. This product is set to support various product launches in the US, showcasing Döhler’s commitment to innovation within the protein landscape.
Investment and Collaboration
Döhler Ventures has invested an undisclosed sum in Superbrewed Food, with plans to enhance production capacity for SB1 and advance its commercialization by 2027. The ingredient itself boasts over 88% protein, along with significant levels of B vitamins, iron, and zinc. It has a neutral taste, excellent pH stability, and good emulsification properties, making it applicable for protein beverages, snacks, and yogurts.
In 2024, SB1 received a GRAS “no questions” letter from the FDA, indicating regulatory acceptance and facilitating its entry into the market. The partnership with industry giants Fonterra and Bel Brands highlights its versatility and broad appeal.
Innovation in Protein Production
Rodrigo Hortega de Velasco, managing partner at Döhler Ventures, underlined SB1’s potential as a “differentiated innovation.” The strategic investment and partnership with Superbrewed aim to scale SB1 globally, emphasizing its competitive pricing compared to traditional protein sources.
Dr. Bryan Tracy, founder and CEO of Superbrewed, noted the ingredient’s efficiency in delivering high protein levels without compromising taste or texture. For example, incorporating 35g of fully digestible protein into a beverage with SB1 can be achieved using just five ounces of water, significantly reducing the quantity needed for other protein sources.
Challenges in Scaling Production
Despite the promising developments, challenges remain for the fermentation industry. Dr. Tracy commented on the shortcomings of various startups that enter agreements with contract manufacturing organizations (CMOs) lacking the necessary infrastructure and experience. He highlighted the importance of full technology transfer to ensure reliability and quality in production.
Tracy pointed out that each startup’s unique needs often require substantial capital investment into their manufacturing partnerships. The complexities of utilizing existing facilities add to the hurdles faced in scaling production effectively in the competitive market.
Sustainable Production Methods
In contrast to other fermentation companies, Superbrewed maximizes its output by harvesting the entire microbial biomass. This ensures a whole food ingredient rather than generating waste. The company utilizes a non-genetically engineered bacterium that thrives in an anaerobic environment, converting various sugars into high-protein yields.
While consuming bacteria may initially seem unappealing to consumers, the concept has been popularized through probiotic products. The postbiotic nature of SB1 means that the bacteria are deactivated, which aligns with consumer preferences while still providing health benefits, as recognized by the International Scientific Association for Probiotics and Prebiotics (ISAPP).
In summary, SB1 represents a breakthrough in high-protein ingredients, offering versatility and advantages over traditional protein sources while navigating the complexities of production scale-up. With ongoing investment and collaboration, Superbrewed Food aims to establish a strong market presence in the evolving protein sector.
The content above is a summary. For more details, see the source article.
